Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pharmacodynamics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,490 result(s) found for: Pharmacodynamics. Displaying page 37 of 75.
    «« First « Previous 33  34  35  36  37  38  39  40  41  Next» Last»»
    EudraCT Number: 2004-001020-20 Sponsor Protocol Number: NKV101983 Start Date*: 2005-01-25
    Sponsor Name:GlaxoSmithKline Group of Companies
    Full Title:
    Medical condition: Chemotherapy Induced Nausea and Vomiting (CINV) 0 Moderately Emetogenic Chemotherapy (MEC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IE (Completed) SK (Completed) HU (Completed) AT (Completed) GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-001638-27 Sponsor Protocol Number: FFP104-001 Start Date*: 2014-10-15
    Sponsor Name:Fast Forward Pharmaceuticals, B.V.
    Full Title: A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed with Primary Biliary Cirrhosi...
    Medical condition: Primary Biliary Cirrhosis (PBC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002823-34 Sponsor Protocol Number: 27818 Start Date*: 2007-11-08
    Sponsor Name:Merck Serono International S.A
    Full Title: A phase II, multicentre, randomised, assessor.blinded, active-comparator, parallel-group dose finding trial to evaluate AS900672-Enriched versus follitropin alfa (GONAL-f) in oligo-anovulatory infe...
    Medical condition: oligoanovulatory infertile women who are candidates for ovulation induction (OI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033312 Ovulation induction PT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended) FR (Completed) DE (Prematurely Ended) IT (Prematurely Ended) ES (Completed) DK (Completed) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001966-27 Sponsor Protocol Number: AGB002 Start Date*: 2016-09-07
    Sponsor Name:Archigen Biotech Limited
    Full Title: A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients w...
    Medical condition: Low Tumor Burden Follicular Lymphoma (LTBFL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) GB (Completed) CZ (Completed) BG (Completed) FR (Completed) LV (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002106-13 Sponsor Protocol Number: ATH3G10-005 Start Date*: 2017-09-06
    Sponsor Name:Athera Biotechnologies AB
    Full Title: Double-blind, randomised, placebo-controlled, multicentre, Phase IIa study to investigate the effect of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together ...
    Medical condition: Arterial inflammation in subjects with elevated lipoprotein a (Lp[a])
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000022953 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003570-77 Sponsor Protocol Number: SB010/04/2012 Start Date*: 2012-12-04
    Sponsor Name:sterna biologicals GmbH & Co. KG
    Full Title: Clinical study to investigate safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with mild aller...
    Medical condition: The trial will be conducted in 38 male patients with mild allergic asthma and documented or known biphasic reaction to allergen challenge (AC).
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002172-92 Sponsor Protocol Number: AZA-AML-004 Start Date*: 2015-04-27
    Sponsor Name:Celgene Corporation
    Full Title: A randomized, multicenter, open-label, Phase 2 study with a safety run-in part to evaluate safety, pharmacodynamics and efficacy of azacitidine compared to no anticancer treatment in children and...
    Medical condition: Treatment of children and young adults with molecular relapse of acute myeloid leukemia (AML) after first complete remission (CR1).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019095-70 Sponsor Protocol Number: LPA112186 Start Date*: 2010-09-16
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-006561-89 Sponsor Protocol Number: CA196-004 Start Date*: 2009-06-30
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) versus Bevacizumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal C...
    Medical condition: Second-Line Treatment for Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002150-31 Sponsor Protocol Number: 20090302 Start Date*: 2012-08-29
    Sponsor Name:Amgen Inc
    Full Title: An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Darbepoetin alfa in Paediatric Subjects From Birth to Less than 1 Year of Age With A...
    Medical condition: Anaemia due to chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    14.1 10005329 - Blood and lymphatic system disorders 10002272 Anemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000870-39 Sponsor Protocol Number: CHDR1607 Start Date*: 2017-08-21
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase 2, randomized, vehicle-controlled, double-blind study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide i...
    Medical condition: HPV-induced genital lesions of immunocompromised and immunocompetent patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016515 10018182 Genital warts LLT
    20.0 100000024086 10064455 HSIL LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003371-29 Sponsor Protocol Number: FIL_ReRi Start Date*: 2016-09-15
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A combination of Lenalidomide and Rituximab as front line therapy for the treatment of elderly frail patients evaluated in CGA with Diffuse Large B-cells non-Hodgkin Lymphoma. A phase II study of t...
    Medical condition: Diffuse Large B-cells non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001021-22 Sponsor Protocol Number: NKO101287 Start Date*: 2005-02-08
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 m...
    Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-000469-35 Sponsor Protocol Number: CL03-ORY-1001SCLC Start Date*: 2018-10-10
    Sponsor Name:Oryzon Genomics S. A.
    Full Title: A pilot study to assess the safety, tolerability, dose finding and efficacy ORY-1001 in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cel...
    Medical condition: Relapsed, extended-stage disease small cell lung cancer (ED SCLC).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10041071 Small cell lung cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004807-31 Sponsor Protocol Number: CAI001 Start Date*: 2019-06-03
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Multicenter, Randomized, Placebo-Controlled Investigator-Blind, Participant-Blind Study to Evaluate Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Trans...
    Medical condition: Chronic Allograft Injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10063209 Chronic allograft nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002221-29 Sponsor Protocol Number: VIT-2763-THAL-201 Start Date*: 2020-02-25
    Sponsor Name:Vifor (International) Inc.
    Full Title: A Phase 2a, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Study on Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Doses of...
    Medical condition: Non-transfusion Dependent Beta-thalassaemia.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10074355 Non-transfusion dependent thalassaemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001519-10 Sponsor Protocol Number: ALN-GO1-008 Start Date*: 2022-04-25
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients with Recurrent Calcium Oxalate Kidney Stone Di...
    Medical condition: Recurrent calcium oxalate kidney stone disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10023436 Kidney stone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000963-22 Sponsor Protocol Number: VTX-801_CLN_001 Start Date*: 2021-10-18
    Sponsor Name:Vivet Therapeutics SAS
    Full Title: A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients with Wilson’s Disease
    Medical condition: Wilson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10047988 Wilson's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005167-51 Sponsor Protocol Number: CA057-003 Start Date*: 2022-08-24
    Sponsor Name:Celgene Corporation
    Full Title: An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Nove...
    Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001827-11 Sponsor Protocol Number: VX19-445-107 Start Date*: 2020-04-24
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445/TEZ/IVA Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 33  34  35  36  37  38  39  40  41  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 09:52:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA